About 15–20% of BC patients show HER2 amplification and/or HER2 over-expression, which are associated with increased tumor aggression and poor prognosis, although these patients are eligible for HER2-directed therapy [3–6]. The gene discussed is ERBB2; the disease is neoplasm.